Specific killing of latently HIV-1-infected cells after provirus reactivation
Specific killing of latently HIV-1-infected cells after provirus reactivation
批准号:
8600241
负责人:
Qigui Q Yu
金额:
$23.4万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-01-01 至 2015-03-31
关键词:
Anti-Retroviral AgentsAntibodiesAntibody FormationAutologousBiological AssayCD4 Positive T LymphocytesCell LineCellsComplementComplement ActivationCytolysisDetectionDiagnosticFailureGene ExpressionGoalsGrantHIV-1Highly Active Antiretroviral TherapyHumanImmune responseImmunityIn VitroIndividualInfectionInterleukin-7LifeMeasurableMediatingMedicalMemoryModelingMorbidity - disease ratePatientsPharmaceutical PreparationsPhaseProductionProliferatingProvirusesReportingResearchResidual stateRestSerumSurfaceT-LymphocyteTestingVaccinesValproic AcidViralViral Cytopathogenic EffectViral ProteinsViremiaVirionVirusVorinostatantiretroviral therapycell typeeffective therapyexperienceglobal healthimprovedin vivoinhibitor/antagonistinnovationkillingsmembermortalitynovel strategiespandemic diseaseprostratinpublic health relevancepurge
中文摘要
说明(由申请人提供):艾滋病毒-1流行病夺走了2 000多万人的生命,目前全世界有3 860万人受到感染,并将继续成为一个重要的群体
英文摘要
DESCRIPTION (provided by applicant): The HIV-1 pandemic has claimed over 20 million lives, with 38.6 million people worldwide currently infected, and will continue to be a significant
global health problem as there is no vaccine available. Currently, the only effective treatment available to HIV-1 infection is HAART (highly active antiretroviral therapy), which has led to a profound reduction in HIV-1-related morbidity and mortality. However, HAART fails to eliminate the virus in vivo, mainly due to the persistent existence of long-lived latently-infected cells harboring replication-competent proviruses. Efforts to purge these infected cells have focused on reactivation of the proviruses. It is presumed that these infected cells will be killed after reactivation of virus gene expression by viral cytopathic effects (CPEs), host immune responses or both. Several stimulants including IL-7, valproic acid (VPA), suberoylanilide hydroxamic acid (SAHA) and prostratin have been explored to force activation of proviruses in latently-infected resting CD4+ T cells that constitute the major reservoir of HIV-1 in vivo. However, treatment with IL-7 or VPA in patients on HAART has failed to reduce HIV-1 latency, suggesting that these agents alone are not sufficient to induce killing of latently-infected cells. We propose to develop
an "activation-killing" approach by combining provirus stimulants with an agent that is able to allow anti-HIV-1 immunity naturally mounted in patients during HIV-1 infection to specifically kill
latently-infected cells after provirus reactivation. Studies have shown that both HIV-1-infected cells and virions use their surface regulators of complement activation (RCA) to resist antibody- dependent complement-mediated lysis (ADCML), which explains why vigorous and sustained anti-HIV-1 envelope (Env) antibody (Ab) responses in almost all infected individuals fail to control HIV-1 infection. We and others have reported that blocking human CD59 (hCD59), a key member of RCA, renders both HIV-1-infected cells and virions sensitive to ADCML. We therefore hypothesize that addition of an hCD59 inhibitor to SAHA, prostratin or both will enable anti-HIV-1 Env Abs naturally present in HIV-1-infected individuals to trigger ADCML of latently-infected T cells after provirus reactivation. The provirus stimulants will activate proviruses to express viral proteins on the surface of latently-infected cells that will be killed by ADCML if hCD59 is inhibited. We will use the human T cell line ACH2, a well-characterized model of HIV-1-latency, to develop such an approach (Aim 1, R21 Phase). We will verify whether the approach is able to trigger ADCML of the primary CD4+ T cells latently infected with HIV-1 in vitro (Aim 2, R33 Phase). We will then determine if this approach can allow anti-HIV-1 Abs naturally present in the sera of infected patients to trigger autologous ADCML of their own latently-infected resting CD4+ T cells (Aim 3, R33 Phase). Our project is innovative and significant because we aim to develop a novel approach for purging the persistent reservoir of HIV-1 in patients on HAART. This approach may simultaneously target various latently infected cells and residual viremia, potentially leading to a broader impact and improved efficacy against the various persistent HIV-1 reservoirs.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Alcohol's impact on immunological and virological profiles in HIV patients
-
批准号:10022081
-
项目类别:
-
资助金额:$34.8万
-
财政年份:2017
-
负责人:Qigui Q Yu
-
依托单位:
Alcohol's impact on immunological and virological profiles in HIV patients
-
批准号:10245323
-
项目类别:
-
资助金额:$30.18万
-
财政年份:2017
-
负责人:Qigui Q Yu
-
依托单位:
Alcohol's impact on immunological and virological profiles in HIV patients
-
批准号:9408187
-
项目类别:
-
资助金额:$15.28万
-
财政年份:2017
-
负责人:Qigui Q Yu
-
依托单位:
Targeting latently infected Tfh cells to achieving a functional cure of HIV-1
-
批准号:8892533
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2015
-
负责人:Qigui Q Yu
-
依托单位:
Targeting latently infected Tfh cells to achieving a functional cure of HIV-1
-
批准号:9014496
-
项目类别:
-
资助金额:$38.62万
-
财政年份:2015
-
负责人:Qigui Q Yu
-
依托单位:
Targeting latently infected Tfh cells to achieving a functional cure of HIV-1
-
批准号:9232988
-
项目类别:
-
资助金额:$38.61万
-
财政年份:2015
-
负责人:Qigui Q Yu
-
依托单位:
Specific killing of latently HIV-1-infected cells after provirus reactivation
-
批准号:9040568
-
项目类别:
-
资助金额:$38.64万
-
财政年份:2013
-
负责人:Qigui Q Yu
-
依托单位:
Specific killing of latently HIV-1-infected cells after provirus reactivation
-
批准号:9276563
-
项目类别:
-
资助金额:$38.64万
-
财政年份:2013
-
负责人:Qigui Q Yu
-
依托单位:
Specific killing of latently HIV-1-infected cells after provirus reactivation
-
批准号:8462367
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2013
-
负责人:Qigui Q Yu
-
依托单位:
Development of Molecular Adjuvants for Therapeutic HIV-1 Vaccines
-
批准号:7762618
-
项目类别:
-
资助金额:$18.88万
-
财政年份:2007
-
负责人:Qigui Q Yu
-
依托单位:
Development of Molecular Adjuvants for Therapeutic HIV-1 Vaccines
-
批准号:7283851
-
项目类别:
-
资助金额:$17.3万
-
财政年份:2007
-
负责人:Qigui Q Yu
-
依托单位:
海外基金